Sculptor Capital Management, Inc.
+9.80%
3M Return
$10.830
-0.030 (-0.28%)終値時点
Churchill Capital Corp XII is a blank check company. The Company is formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company has conducted no operations and has generated no revenue.
Churchill Capital Corp XII (CXII) is currently not a strong buy. The stock is trading at $10.83 with a 5-day change of +1.03% and a 20-day change of +2.17%. However, it has a negative P/E ratio of -11084.69, indicating that the stock is not generating profits at this time. The RSI is at 59.075, suggesting that the stock is nearing overbought territory, which could lead to a pullback. The main risk is the low current ratio of 12.07, which indicates potential liquidity issues despite recent positive earnings of $2,282,907 in Q2 2026. Therefore, while there are some positive indicators, the overall financial health and valuation metrics suggest holding rather than buying.
Churchill Capital Corp XII is a blank check company. The Company is formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company has conducted no operations and has generated no revenue. It operates in the Financials sector.
Churchill Capital Corp XII (CXII) is currently not a strong buy. The stock is trading at $10.83 with a 5-day change of +1.03% and a 20-day change of +2.17%. However, it has a negative P/E ratio of -11084.69, indicating that the stock is not generating profits at this time. The RSI is at 59.075, suggesting that the stock is nearing overbought territory, which could lead to a pullback. The main risk is the low current ratio of 12.07, which indicates potential liquidity issues despite recent positive earnings of $2,282,907 in Q2 2026. Therefore, while there are some positive indicators, the overall financial health and valuation metrics suggest holding rather than buying.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。